

Depth of sedation with dexmedetomidine modulates cortical excitability non-linearly

Authors: Paolo Cardone^{1,2*}, Olivier Bodart^{1,2,3*}, Murielle Kirsch^{4,5}, Julien Sanfilippo⁴, Alessandra Virgillito⁶, Charlotte Martial^{1,2}, Jessica Simon⁷, Sarah Wannez¹, Robert D. Sanders^{8,9}, Steven Laureys^{1,2}, Marcello Massimini^{10,11}, Vincent Bonhomme^{4,5,12*}, Olivia Gosseries^{1,2*}

¹Coma Science Group, GIGA-Consciousness, University of Liège, Liège, Belgium

²Centre du Cerveau², University Hospital of Liège, Liège, Belgium

³Department of Neurology, University Hospital of Liège, Liège, Belgium

⁴Anesthesia and Intensive Care Laboratory, GIGA-Consciousness, University of Liège, Liège, Belgium

⁵Department of Anaesthesia and Intensive Care Medicine, University Hospital of Liège, Liège, Belgium

⁶Department of Rehabilitation, ASL Toscana Nordovest, Italy

⁷Psychology and Neuroscience of Cognition, University of Liège, Liège, Belgium

⁸Specialty of Anaesthetics, University of Sydney, Camperdown, Australia

⁹Department of Anaesthetics & Institute of Academic Surgery, Royal Prince Alfred Hospital, Camperdown, Australia

¹⁰Department of Biomedical and Clinical Sciences “L. Sacco”, Università degli Studi di Milano, Milan, Italy

¹¹IRCCS Fondazione Don Gnocchi, Milan, Italy

¹²University Department of Anaesthesia and Intensive Care Medicine, Centre Hospitalier Régional de la Citadelle (CHR Citadelle), Liège, Belgium

* Contributed equally

Corresponding authors:

27 Olivia Gosseries

28 Coma Science Group, GIGA-Consciousness

29 Avenue de l'hôpital 1

30 4000 Liege

31 Belgium

32 ogosseries@uliege.be

33

34 Keywords: Anaesthesia, Dexmedetomidine, TEP, TMS-Evoked Potential, Consciousness,

35 Responsiveness, TMS, TMS-hdEEG

Abstract

Background

Cortical excitability changes across conscious states, being higher in unconsciousness compared to normal wakefulness. Anaesthesia offers controlled manipulation to investigate conscious processes and underlying brain dynamics. Among commonly used anaesthetic agents, dexmedetomidine (DEX) effects are not completely known. In this study, we investigated cortical excitability as a function of DEX sedation depth.

Methods

Transcranial magnetic stimulation coupled with electroencephalography was recorded in 20 healthy subjects undergoing DEX sedation in four conditions (baseline, light sedation, deep sedation, recovery). Frontal and parietal cortices were stimulated using a neuronavigation system. Cortical excitability was inferred by slope, amplitude, positive and negative peak latencies of the first component (0-30 ms) of the TMS-evoked potential. Four Generalized Linear Mixed Models (GLMM) were used to test the effect of condition and brain region over cortical excitability.

Results

Dexmedetomidine modulated amplitude ($P < 0.001$), slope ($P = 0.0001$) and positive peak ($P = 0.042$), while the targeted brain region affected amplitude ($P < 0.001$), slope ($P < 0.001$), and negative peak ($P = 0.001$). The interaction between dexmedetomidine and region had an effect over amplitude ($P = 0.004$), and slope ($P = 0.009$) such that cortical excitability was higher during all conditions where DEX was present as compared to the baseline.

Conclusions

Cortical excitability changes non-linearly as a function of the depth of DEX sedation, with a paradoxical non dose-dependent increase. The effect is region-specific, being present in the frontal but not in the parietal region. Future research should extend the current results with other anaesthetics to better understand the link between cortical excitability and depth of sedation.

Introduction

Anaesthesia offers a unique medium to unveil consciousness mechanisms, modulating reversibly different aspects of consciousness states, depending on the nature of the drug and its dosage (for a recent review, see¹). When an anaesthetic agent leads to an alteration of consciousness, it impacts the brain functioning in its complexity², connectivity³, and frequency range⁴. After regaining consciousness, people might experience emergence agitation, postoperative delirium, a cognitive disorder characterised by anxiety, cognitive alterations, and/or hypo- or hyperactivity.⁵

Dexmedetomidine (DEX) is an α_2 -adrenoceptor agonist that has the potential of reducing the incidence of emergence agitation⁶ and postoperative delirium compared to other anaesthetic agents⁷. The reasons for these phenomena are still unclear. The anxiolytic, analgesic and opioid sparing properties of the molecule, as well as the absence of anticholinergic effects, improvement of sleep quality, and eventually attenuation of postoperative inflammation have been advocated to explain the reduction in the incidence of postoperative delirium⁸. Moreover, a possible quicker transition between brain states and quicker restoration of cortical communication might explain the positive effect on emergence agitation. Through its inhibiting effect on the locus coeruleus, DEX reduces the inhibition of the ventrolateral preoptic nucleus (VLPO) of the hypothalamus, which in turn exerts GABAergic inhibition of cortical arousal nuclei. This effect on subcortical sleep systems promotes a state similar to stage 2/3 non-REM sleep.⁹⁻¹¹ After DEX intake, cortical and subcortical regions glucose consumption decreases, which correlates with the functional connectivity impairment in intrinsic consciousness networks, as well as between the thalamus and cortical regions within those networks.^{11 12} Network topology is also modified by DEX.¹³ Interestingly, the cortico-cortical connectivity remains partially preserved during deep sedation.¹² This asymmetry between cortical and subcortical regions might account for partially preserved semantic processing of incoming stimuli after the loss of responsiveness, as indexed by electroencephalography (EEG).¹⁴ Also, functional connectivity between the thalamus and key structures of arousal and

saliency detection networks is relatively preserved during DEX-induced deep sedation, which may explain the ability to rapidly restore responsiveness by vigorous external stimulation. Thus, responsiveness and information processing are modulated by DEX-induced modifications in brain activity. Finally, DEX drives a shift towards slow-wave oscillation^{15 16}, while high-frequencies power (i.e., beta) can accurately predict responsiveness upon behavioural assessment¹⁷. These findings pave the way to investigate the link between responsiveness, depth of sedation, and relative cortical modulation.

Transcranial magnetic stimulation coupled with high-density electroencephalography (TMS-hdEEG) assesses brain response with a no-task paradigm, bypassing sensory cortices. TMS-hdEEG is a non-invasive neurostimulation technique that perturbs the brain through a local and fast change of the magnetic field. This change induces an electrical current that mimics physiological activity, leading to an endogenous-like response to the pulse. TMS-evoked potential (TEP), the averaged EEG response to the TMS pulse, captures the neural response.^{2 3} TEP at the nearest electrode to the stimulation side provides information on the local modulation of the TMS. We can operationally define cortical excitability as the amplitude, slope, and positive/negative response latencies of the first component (0-30 ms), although we remain blinded to the underlying neuronal events. Cortical excitability as measured this way is modulated by conscious states¹⁸, circadian rhythms, sleep, and sleep deprivation^{19 20}. It also increases during unresponsive states such as NREM sleep²¹ and attentional lapses²², standing as a promising method to investigate reactivity of the cortex in time and space as a function of conscious states.

In this study, we aimed to directly inquire DEX effects over cortical excitability during different levels of sedation [namely no sedation (baseline), light sedation, absence of volitional response to command (deep sedation), and recovery of volitional response (recovery)]. Following the effects described in sleep, we expected cortical excitability to proportionally increase with depth of sedation. We hypothesised that cortical excitability would be the highest during deep sedation,

- 111 while there would be virtually no difference between baseline and the recovery condition after DEX
- 112 intake, where subjects show behavioural responsiveness.

Methods

Participants

A priori power analysis and sample size estimation were difficult given the scarcity of research on TEPs, anaesthesia and cortical excitability. We aimed to include at least 20 subjects, as this is in the range of most TMS-hdEEG studies.^{2 22} Considering drop-out and possible technical problems, we recruited thirty healthy subjects on the university campus between February 2015 and May 2016. Participants were screened by a senior anaesthesiologist (VB) to control for the absence of any contraindications to DEX sedation, TMS, and MRI. We recruited adult healthy volunteers on the university campus with the following inclusion criteria: more than 18 years, absence of prior neurological, neurosurgical, or psychiatric history, no history of adverse events during anaesthesia or previous exposure to dexmedetomidine, no active chronic illness or medication, no contraindication to MRI, and no ongoing pregnancy for female participants (efficient contraception or negative pregnancy test required before inclusion). Five participants were dismissed because artefact-free TEPs could not be obtained reliably during normal wakefulness, two lost interest in the study, and two were dropped for technical or logistical reasons. One subject had a minor adverse reaction to DEX infusion (pruritus without a rash or any other symptoms or signs), for which the experiment was aborted. Twenty subjects completed the entire experiment (see **Table 1**). All subjects gave their written informed consent. The study was approved by the Ethics Committee of the University and University Hospital of Liège, Belgium (number B707201422895, professor V. Seutin).

Experimental protocol

A visual summary of the protocol can be found in **Figure 1**. After a first screening, eligible participants underwent an MRI and a TMS-hdEEG pretest during normal wakefulness to find the most suitable brain target under stimulation of the superior parietal (Precuneus - Brodmann area 7) and premotor region (Brodmann area 6) at the midline. These brain targets were set for the

138 experimental phase using neuronavigation (Nexstim, Helsinki, Finland). During the experiment,
139 subjects lied on their back while venous access was installed to infuse the drug. DEX was
140 administered intravenously using a target-controlled infusion device (TCI, height-adjusted model of
141 Dyck²³), providing a constant estimation of DEX plasma concentration. DEX target concentration
142 was changed by steps of 0.5 ng mL⁻¹ to achieve the desired behavioural state. Once attained, a 5-
143 minute equilibration period without any change in target concentration allowed equilibration of
144 concentrations between pharmacokinetic compartments, and a blood sample was drawn
145 immediately before and after data acquisition for off-line DEX plasma concentration measurement
146 via high performance liquid chromatography-mass spectrometry, or HPLC-MS (see Appendix). The
147 behavioural assessment of depth of sedation was performed at the same times using the University
148 of Michigan Sedation Scale (UMSS)²⁴ and Ramsay Scale²⁵. There were four conditions for each
149 subject: “baseline”, before DEX administration; light sedation, marked by drowsiness; deep
150 sedation, characterised by no behavioural response; recovery, with regaining in response. During
151 the whole study, physiological parameters were monitored (ECG, peripheral blood oxygen
152 saturation by pulse oximetry, and end-tidal CO₂ levels). After a baseline TMS-hdEEG recording,
153 DEX was increased to reach drowsiness. A 5-minute break allows concentration to stabilise,
154 reaching light sedation, during which subjects were still able to follow a command. The level of
155 DEX was then incremented by 0.5 ng mL⁻¹ steps to induce unresponsiveness, alias deep sedation.
156 For security reason, we did not exceed 2.5 ng mL⁻¹. Lastly, the DEX concentration was decreased
157 by 0.5 ng mL⁻¹ steps to regain responsiveness to command, which was referred as the recovery
158 condition. Once responsiveness had returned, the attained concentration was maintained constant
159 for the duration of recordings.




Figure 1: Diagram of the protocol plotted over time (x-axis, arbitrary scale) and DEX concentration (y-axis, arbitrary scale). Four conditions were set (Baseline, Light Sedation, Deep Sedation, Recovery) based on behavioural assessment. TMS-hdEEG sessions over the parietal and frontal regions were performed in each stable condition, for a total of 8 sessions per subject.

Data acquisition

Magnetic resonance imaging

High-resolution structural MRI was performed on a 3-Tesla MR scanner (Allegra Prisma, Siemens, 3D isometric 1x1x1mm T1) during wakefulness, on pretesting day, just before the TMS-hdEEG session. For each participant, diffusion-weighted imaging data was acquired (not used in the study). T1 was used to perform TMS neuronavigation on the individual cortex.

TMS-hdEEG

A focal bipulse 8-coil (Nexstim, Helsinki, Finland) with a 3D infrared tracking position sensor was used to perform TMS delivery. Neuronavigation was implemented using glasses head tracker and the Navigated Brain Stimulation (NBS) system (Nexstim Ltd., Helsinki, Finland) that uses T1-

weighted structural MR images to set stimulation target. A 64-channel TMS-compatible EEG amplifier (Eximia, Helsinki, Finland), equipped with a sample-and-hold circuit to provide TMS-artefact-free data from 5 ms post-stimulation, was used to record concurrent EEG data during TMS stimulation. Electro-oculogram (EOG) was recorded with two bipolar electrodes. EEG signal was band-pass filtered between 0.1 and 500 Hz and sampled at 1450 Hz. Prior to each recording session, electrodes impedance was set below 5 k Ω . Stimulation target and intensity were set during the pretest and were kept constant across all conditions. Left premotor and left parietal cortices were targeted and the stimulation target was chosen if there was a good TEP with no artefact. The intensity was adjusted individually to get a good signal-to-noise ratio, with an evoked electric field intensity at the cortical surface between 100 and 150 Vm⁻¹. Each condition had between 200 and 250 trials, with a frequency of 0.5 Hz and a jitter of ± 200 ms. A thin foam layer under the TMS coil and white noise mask were used to minimize somatosensory stimulation and auditory evoked potentials caused by the TMS click, respectively.

Behavioural assessment

Behavioural assessment of depth of sedation was performed using the UMSS²⁴ and Ramsay Scale²⁵. The four conditions had different behavioural profiles: baseline, previous to the DEX administration, was marked by a clear command-following to the verbal request ‘squeeze my hand’ (Ramsay score 2, UMSS 0); light sedation was marked by drowsiness (Ramsay score 3-4, UMSS 1-2); deep sedation was characterised by no behavioural response to any verbal command (Ramsay score 6, UMSS 4); recovery was distinguished by regaining in response after deep sedation (Ramsay score 3-4, UMSS 1-2). To exclude possible automatic response to command, other minor attentional and memory tasks were performed. These tasks included predetermined questions about simple subtractions and autobiographical memory recalls (not analysed here).

200 **Blood sampling**

201 Before and after each session we took a blood sample to calculate the real plasmatic DEX
202 concentration. The sample was anonymized and stored at -20°C before being analysed by Orion
203 Pharma. For more information about the blood sampling and analysis, see Appendix.

205 **Data analysis**

206 **Preprocessing of TMS-hdEEG data**

207 Data were analysed using MATLAB (The Mathworks Inc., Natick, MA). Trial rejection was
208 performed manually with SSP (SiSyphus Project) to eliminate trials with magnetic artefacts or
209 ocular/muscular movements. Channels with a high level of noise were rejected. A first 1 Hz high
210 pass filter was applied to continuous data to eliminate slow oscillating noise. Afterwards data were
211 downsampled to 1000 Hz, then lowpassed to 80 Hz. Data were subsequently epoched from -100 to
212 300 ms post-stimulation. A baseline correction between -100 and -1.5 ms was applied. Trials were
213 then averaged, using robust averaging method, to minimize noise. For more details, see previous
214 publications where the same methods were applied.^{19 20 22}

215 **Cortical excitability computation**

216 Cortical excitability was inferred from the amplitude, the slope, the positive and negative latency of
217 the first component of the TEP, between 0 and 30 ms post-TMS. The TEP was extracted at the
218 closest electrode to the stimulation point that did not present any artefact (distance of the electrode
219 from the hotspot, mean $\pm$ SD, 39.29 ± 14 mm). The latency of the negative peak is the time delay
220 between the stimulation (t_N) and the moment at which the TEP is minimum, and ranges between 9
221 and 15 ms, while the latency of the positive peak (t_P) is the time delay between the stimulation and
222 the moment at which the TEP is maximum, and ranges between 10 and 30 ms. The amplitude refers
223 to the peak-to-peak amplitude ($A_{t_P} - A_{t_N}$), which is the microvolt change between peak (A_{t_P}) and

trough (A_{t_N}), while the slope is the maximum change of the first component between t_P and t_N . More details can be found in previous works.^{19 20 22} For a visual intuition, see **Figure 2**.




Figure 2: Measures of cortical excitability in the TEP (average TMS-hdEEG responses over trials). The red flash indicates the TMS pulse. We measured the peak-to-peak amplitude of the TEP in μV (here, around 6 μV), the latency in milliseconds of the negative peak (here, around 10 ms) and of the positive peak (here, around 20 ms), and the maximal slope of the curve in voltage over time ($\mu V \text{ ms}^{-1}$). Note that here the slope is represented with the tangent line at the inflection point.

Statistics

We run four Generalized Linear Mixed Models (GLMMs) on SPSS (IBM® SPSS® Statistics 27), to test the effect of condition (depth on anaesthesia: baseline, light sedation, deep sedation, and recovery) and stimulated brain region (frontal and posterior) over cortical excitability (amplitude, slope, positive, and negative latencies). The model took into consideration the attained DEX concentration as covariate, and the characteristics of the TMS pulse such as the Mean Induced Electric Field (V/m) and the distance of the electrode from the stimulation point in millimetres as random effects. Given that seven participants were still behaviourally responsive in the deep

sedation condition (Ramsay score 3-4, UMSS 1-2 instead of the expected scores of 6 and 4, respectively), responsiveness at any condition was considered in the model as covariate (responsive vs unresponsive). Pairwise comparisons between conditions were performed with Bonferroni-adjusted two-tailed t-tests. We considered amplitude as the primary endpoint [$P_{\text{critical}} = 0.05/(2 \text{ locations} \times 4 \text{ conditions}) = 0.006$], and slope, positive and negative latencies as secondary endpoints [$P_{\text{critical}} = 0.05$].

Results

We modulated drug concentration to induce different conditions (sedation depth), which lead to different behavioural responses. The attained concentrations, as measured in the plasma for each condition were (mean $\pm$ SD, in ng mL⁻¹): baseline: 0 ± 0 ; light sedation: 1.37 ± 0.47 ; deep sedation: 3.41 ± 0.778 ; recovery: 2.71 ± 0.47 . The UMSS score was (median, range): baseline: 0, [0 0]; light sedation: 2, [1 3]; deep sedation: 4, [2 6]; recovery: 2, [1 4]. Ramsay (median, range): baseline: 2, [2 2]; light sedation: 3, [3 4]; deep sedation: 6, [3 6]; recovery: 3, [2 5]. Interestingly, 7 out of 20 subjects were still responsive in deep sedation. As said before, we did not want to exceed our theoretical security threshold of a 2.5 ng mL⁻¹ theoretical target to ensure the safety of our subjects. For more information about the participants, see **Table 1** and Appendix (**Table A1**).

Measure	Statistics
Female (Male)	9 (11)
Age	23.85 ± 2.43
Height (cm)	173.65 ± 8.42
Weight (kg)	70 ± 13.71
BMI	23.10 ± 3.40

Distance Electrode	Frontal: 31.20 ± 11.21 Parietal: 47.40 ± 11.80
DEX concentration [measured; concentration predicted by the model (ng mL^{-1})]	Baseline: 0 ± 0 ; 0 ± 0 Light: 1.37 ± 0.47 ; 1.3 ± 0.30 Deep: 3.41 ± 0.78 ; 2.35 ± 0.24 Recovery: 2.71 ± 0.47 ; 1.74 ± 0.31

259


260 **Table 1:** Demographics and descriptive statistics of variables. Where continuous variable, we
261 present mean and standard deviation (mean $\pm$ SD); where categorical, we show the count for each.

262

263 According to our hypothesis, we found that condition (depth of sedation) modulated cortical
264 excitability (see **Figure 3**). As shown in **Table 2**, and according to the GLMM models, there was a
265 significant interaction between depth of sedation condition and stimulation location for amplitude
266 [$F_{(3, 149)} = 4.594$, $P = 0.004$] and slope [$F_{(3, 149)} = 4.009$, $P = 0.009$], but not for the negative or
267 positive peak latencies. Post hoc analysis (**Table 3**) showed that baseline amplitude in the frontal
268 cortex was significantly different to the one in light sedation (Adjusted $P < 0.0001$), deep sedation
269 (Adjusted $P = 0.003$) and recovery (Adjusted $P < 0.001$), while the slope in the frontal cortex was
270 different in all pairwise contrasts (Adjusted $P < 0.023$), except for the deep sedation and recovery
271 contrast (Adjusted $P = 0.258$). Slope and amplitude had the highest mean value in light sedation.
272 These differences were not seen in the parietal region. Depth of sedation (**Table 2**) had an effect on
273 positive peak latency [$F_{(3, 149)} = 2.807$, $P = 0.042$], but not on the latency of the negative peak
274 [$F_{(3, 149)} = 0.132$, $P = 0.22$]. Irrespective of region, positive peak latency was significantly longer at
275 light sedation than at baseline (Adjusted $P = 0.030$) (**Table 3**). The stimulated region (frontal vs.
276 parietal) had an effect on negative peak latency [$F_{(1, 149)} = 10.498$, $P = 0.001$], meaning that it was

277 globally significantly longer in the parietal region than in the frontal one, but no effect over the
 278 positive peak latency [$F_{(1, 149)} = 1.234$, $P = 0.268$]. Responsiveness to command had no effect on
 279 studied parameters (**Table 3**). **Figure 4** shows the effect of conditions and brain regions over
 280 cortical excitability. For more detailed information about the values of cortical excitability, see
 281 Appendix (**Table A2-A3**). We also removed the two subjects who showed the strongest effects (z -
 282 score >3) to test robustness of our findings and had virtually the same results with just small
 283 variations (see Appendix).

284



285

286 **Figure 3:** Grand average of the TMS-Evoked Potentials (TEPs) for all the subjects, divided by
 287 region (Frontal and Parietal) and the depth of sedation (baseline, light sedation, deep sedation,
 288 recovery).




Figure 4: Averaged (black line) and individual results (grey line) of cortical excitability measurements (amplitude (A), slope (B), latency of negative peak (C) and latency of positive peak (D)) for the four conditions (baseline, light sedation, deep sedation, recovery). Each condition is divided according to the region (frontal vs. parietal). Error bars correspond to the standard error of the mean (SEM). The biggest change in amplitude and slope appears in the frontal cortex during light sedation in comparison to the other three conditions. For the image without the subjects who displayed the strongest effect, see Appendix (**Figure A1**). Legend: * = $p < 0.05$, ** = $p < 0.01$; *** = $p < 0.001$

Dependent Variables	Independent variables				
	Condition*	Condition	Region (Frontal vs. Parietal)	DEX concentration	Responsiveness to command
	Region				

Amplitude	F_(3, 149) = 4.594 P = 0.004	F_(3, 149) = 9.091 P < 0.001	F_(1, 149) = 34.566 P < 0.001	F _(1, 149) = 3.013 P = 0.085	F _(1, 149) = 0.858 P = 0.356
Slope	F_(3, 149) = 4.009 P = 0.009	F_(3, 149) = 5.66 P = 0.001	F_(1, 149) = 50.282 P < 0.001	F _(1, 149) = 3.352 P = 0.069	F _(1, 149) = 0.003 P = 0.954
Latency of negative peak	F _(3, 149) = 0.231 P = 0.875	F _(3, 149) = 0.132 P = 0.941	F_(1, 149) = 10.498 P = 0.001	F _(1, 149) = 0.830 P = 0.364	F _(1, 149) = 0.069 P = 0.793
Latency of positive peak	F _(3, 149) = 2.154 P = 0.96	F_(3, 149) = 2.807 P = 0.042	F _(1, 149) = 1.234 P = 0.268	F _(1, 149) = 1.105 P = 0.295	F _(1, 149) = 0.002 P = 0.964

299

300 **Table 2.** Results of the Generalized Linear Mixed Model (GLMM) on the modulation of cortical
301 excitability. We took into consideration the condition (baseline, light sedation, deep sedation and
302 recovery), the stimulated region (frontal vs. parietal), their interaction, the DEX concentration in the
303 blood, and whether subjects were responsive in deep sedation. Significant effects in **bold**. Mean
304 values and standard deviation of each measurement for condition are reported in the Appendix
305 (**Table A2**).

306

Pairwise comparisons in the frontal region for amplitude and slope					
Measure	Contrast	Estimate of the mean difference	Adjusted P	95% Confidence interval	
				Inferior	Superior
Amplitude	Baseline – Light	-6.519	<0.001	-9.852	-3.186
	Baseline – Deep	-4.553	0.003	-7.877	-1.230
	Baseline – Recovery	-5.027	<0.001	-8.192	-1.863
	Light – Deep	1.966	0.084	-0.180	4.111
	Light – Recovery	1.492	0.130	-0.326	3.309
	Deep - Recovery	-0.474	0.230	-1.252	0.304
Slope	Baseline – Light	-0.605	<0.001	-0.958	-0.251
	Baseline – Deep	-0.334	0.022	-0.631	-0.036
	Baseline – Recovery	-0.370	0.007	-0.668	-0.072
	Light – Deep	0.271	0.020	0.031	0.511
	Light – Recovery	0.235	0.022	0.026	0.443
	Deep - Recovery	-0.036	0.258	-0.100	0.027
Contrasts of positive latency					
Contrast		Estimate of	Adjusted P	95% Confidence interval	

	the mean difference		Inferior	Superior
Baseline – Light	-2.278	0.030	-4.419	-0.138
Baseline – Deep	-2.025	0.350	-5.001	0.951
Baseline – Recovery	-2.059	0.230	-4.730	0.612
Light - Deep	0.253	1.000	-1.332	1.839
Light - Recovery	0.219	1.000	-1.262	1.700
Deep - Recovery	-0.035	1.000	-0.903	0.833

Table 3 Post-hoc comparison for amplitude and slope in the frontal cortex, and for positive latency over the depth of sedation conditions. Significant comparisons are represented in **bold**. Since amplitude is our main endpoint, its P_{critical} is set to 0.006, while for slope and positive latency P_{critical} is 0.05.

Covariates as mean induced electric field, which summarize TMS pulse characteristics, and the distance of the electrode from which the TEP was taken, had a significant effect over cortical excitability. These effects are negligible and not informative for our purpose, as they were constant across conditions and had a smaller effect size compared to the effects of condition or brain region. They are reported in the Appendix (**Table A4**).

Discussion

In the current study, we measured changes in cortical excitability as a function of the depth of DEX sedation in 20 healthy subjects, taking into consideration four conditions (baseline, light sedation, deep sedation, and recovery). Cortical excitability at the sensor level has been reported to increase during unconscious states, such as deep NREM sleep or disorder of consciousness like the unresponsive wakefulness syndrome.^{21–26} Thus, we expected cortical excitability to increase proportionally with the depth of sedation, being maximum during the deep sedation. According to our hypothesis, the condition had a strong effect on amplitude and slope. Interestingly, the effect was only present in the frontal cortex, and in contrast to our expectations, was not higher in the deep sedation compared to the light sedation, when subjects were drowsy but still able to respond to a command. To our knowledge, this is the first time that a non-linear evolution of cortical excitability is described under the action of an anaesthetic agent, in a region-specific manner. It is important to remark here that our definition of cortical excitability is purely operational in this context, in that it refers to the amplitude/slope of early TEPs, rather than to the nature of the underlying neuronal events. In fact, various mechanisms may account for the enhancement of early TEPs in DEX, including a stronger driving force in hyperpolarized postsynaptic neurons²⁷, an increased discharge synchrony of cortical populations²⁸, a reduction in synaptic depression^{29–30}, and thalamic bursting triggered by the TMS-induced corticothalamic volley.

The increase of cortical excitability recorded in the frontal cortex is in line with two recent works about spontaneous conscious transition and TEPs.^{22–31} In the first one, cortical excitability of the motor cortex increased during drowsiness, but did not change in unresponsiveness, when participants were allowed to drift towards sleep during a detection task.³¹ In the second one, cortical excitability in the premotor cortex transiently increases during lapses of attention in a continuous attentive task after the usual bedtime, compared to no-lapses periods.²² These evidences support the

idea that the reactivity of the frontal cortex is specifically altered in drowsy conditions where subjects might have impaired (but evident) behavioural responsiveness, as the one here described during light sedation. In congruence with this view, we observed higher amplitude in recovery (that is, after regaining response to command) compared to baseline. Arguably, during recovery, participants were in a state that was closer to light sedation than to baseline, being still drowsy. In other words, our results extend with a chemical manipulation what was previously reported in natural settings. It is however possible that these effects are specific to the sleep-like modulation of DEX and might not extend to other anaesthetics that are not α_2 -adrenergic agonists. If it is an effect of the sedation *per se*, cortical excitability might be a novel index of drowsiness and sedation, whose neural mechanisms should be investigated. However, the absence of the effect in the parietal cortex is a peculiar observation, as there are several reports that highlight the role of parietal regions for the emergence of consciousness.³² Future research should address this phenomenon in more detail.

Drug modulations of TMS-evoked responses are of paramount importance to depict the underlying neural dynamics of the compound, and to bridge neurochemical pathways, brain mechanisms, and behaviour. If there are a number of studies that inferred cortical excitability with TMS looking at changes in the resting state motor thresholds^{33 34}, just a few observed TEPs.^{31 35} One issue is that TEPs (and in general evoked-responses) change from region to region,^{36–38} as proven by the effect of the region over the negative latency (see **Figure 4**). This is relevant, as TEPs might be modulated not only by the depth of sedation *per se*, but by the changes of the oscillatory activity (in a power-³⁸ or a phase-dependent³⁹ manner). In fact, the depth of sedation causes spectral modification, in particular within the beta frequency band, which predicts responsiveness under anaesthesia¹⁷ and wakefulness⁴⁰, and the alpha and delta band, which are modulated by DEX concentration and state of consciousness.¹⁶ As shown in a recent work, alpha and beta activity in Rhesus macaques after DEX anaesthesia differs between loss of consciousness, recovery of consciousness, and the

370 recovery of the task performance at pre-anaesthesia level.⁴¹ Future investigations should pinpoint in
 371 finer details what is the relationship between responsiveness, natural oscillation, and TEPs.
 372
 373 The current study presents strong effects on cortical excitability, with the same trend present in
 374 almost all the subjects we recorded. However, there are still some relevant limitations. First, we
 375 used a behavioural assessment for inferring consciousness. The absence of behavioural responses
 376 does not always coincide with unconsciousness⁴² and subjects may have relatively preserved higher
 377 order cognitive processes (i.e., semantics) during the loss of responsiveness due to DEX.¹⁴ In other
 378 words, one could say that consciousness assessment should be refined with bedside
 379 neurophysiological measurements. Nevertheless, we are confident that our participants were in a
 380 deep sedation even if some were responsive, considered that the DEX concentration in the blood
 381 was very high. Still, the reason why some subjects were still responsive in deep sedation while
 382 others were not is not clear. This may have something to do with the accuracy of the model we used
 383 for target-controlled infusion, and/or to inter-individual variability in the sensitivity to DEX action.
 384 The mechanisms that lead to responsiveness to a certain drug should be approached in a systematic
 385 way. Given that brain dynamics⁴³ and spectral power¹⁶ change after DEX administration in dose-
 386 dependent fashion, different patterns and biomarkers could be used to predict responsiveness. Here,
 387 as shown in **Table 1**, responsiveness in deep sedation had no effect over cortical excitability ($P >$
 388 0.35), so probably it cannot be used to predict responsiveness as it is. Another possible problem is
 389 that we did not randomize the order of light and deep sedation. We cannot exclude that the high
 390 excitability of light sedation is driven just by an order effect. Other studies with randomization
 391 could ensure that this not the case. Additionally, we did not have any free recall after the sessions.
 392 This could have helped to understand the phenomenological status of subjects, even when they did
 393 not show any kind of response to verbal command. Finally, as previously mentioned, a comparison
 394 with other drugs might show the extent of our results and elucidate possible underlying dynamics.

395 This is relevant to comprehend which neuropathways are important in changing cortical excitability
396 and what is its links to sedation in a drug (in)dependent-manner.

397

398 In conclusion, we provide here the first evidence of non-linear evolution of cortical excitability after
399 DEX intake, as indexed by the first component (0-30 ms) of the TEP at the closest electrode to the
400 stimulation hotspot. We demonstrated that DEX sedation increases local cortical excitability in a
401 region-specific manner, but do not differs between sedation level. In particular, we had no
402 difference in cortical excitability between light sedation, deep sedation and recovery. This is in line
403 with recent findings that describe abnormal high cortical excitability during drowsiness in natural
404 settings. Interestingly, the effect was present only in the frontal cortex, and not in the parietal one.
405 These results foster new questions for possible investigations about the nature of sedation and
406 drowsiness that will result in a deeper understanding of cortical dynamics during anaesthesia.

407 Authors' contribution

408 OB, VB, SL and RS designed the study. OB, SW, MK, JS, AV, and VB collected the data. PC
409 analysed the data. Data interpretation was performed by all authors. PC drafted the article with the
410 help of OG and VB. All authors revised it critically for important intellectual content and gave final
411 approval of the revised manuscript.

412 Declaration of interests

413 VB declares that he has received a research grant from Orion Pharma and honoraria for consultancy
414 from Medtronic for the past 6 years. PC, OB, MK, JS, AV, CM, JS, SW, RS, SL, MM & OG
415 declare that they have no conflict of interest.

416 Funding

417 The study was supported by Orion Pharma [unrestricted grant and measurement of plasma
418 dexmedetomidine concentrations, Orion Corporation (Business Identity Code FI 19992126),
419 Orionintie 1, PO Box 65, 02200 Espoo, Finland], the University and University Hospital of Liège,
420 the Belgian National Funds for Scientific Research (F.R.S-FNRS), the European Union's Horizon
421 2020 Framework Program for Research and Innovation under the Specific Grant Agreement No.
422 945539 (Human Brain Project SGA3), the BIAL Foundation, AstraZeneca Foundation, the Generet
423 funds and the King Baudouin foundation, the James McDonnell Foundation, Mind Science
424 Foundation, Mind Care Foundation, IAP research network P7/06 of the Belgian Government
425 (Belgian Science Policy), the Public Utility Foundation 'Université Européenne du Travail', the
426 "Fondazione Europea di Ricerca Biomedica", the Erasmus+ Traineeship, the CUPPD (University of
427 Liège) and the GIGA Doctoral School for Healthy Sciences (University of Liège). O.G. is research
428 associate and S.L. is research director at the F.R.S-FNRS.

429 Acknowledgements

430 We thank all the volunteers who participated in our studies, Gilles Vandewalle for vital support in
 431 the implementation of TMS-hdEEG excitability computation, Mario Rosanova, Simone Sarasso,
 432 Matteo Fecchio, and Renzo Comolatti for valuable discussions on DEX effects and TMS-hdEEG
 433 interpretation. We finally thank Orion Pharma for the quantification of DEX concentration in the
 434 blood.

435 Appendix

436 **Methods – Blood sampling and dexmedetomidine quantification**

437 Sample preparation was performed using solid phase extraction (SPE). Aliquots of 250 µl of plasma
438 were mixed with 675 µl of 0.1% formic acid in water and 75 µl of internal standard solution
439 (medetomidine-d₃, 1 ng/ml). Samples were then extracted with Sep-Pak® tC18 100 mg 96-Well
440 Plates (Waters Corporation, Milford, MA, USA) using an Oasis 96-well plate extraction manifold
441 (Waters). The evaporation residue was dissolved in 100 µl of a solution containing 30 % methanol
442 and 70 % water.

443 The HPLC-MS/MS system consisted of an Agilent 1200 HPLC instrument (Agilent, Santa Clara,
444 California, USA) and an AB Sciex QTrap4000 triple quadrupole mass spectrometer (AB Sciex
445 LLC, Concord, ON, Canada). Separations were performed with Gemini C₁₈ analytical column (150
446 x 2.0 mm, particle size 5 µm; Phenomenex, Torrance, CA, USA)) coupled with Gemini C₁₈
447 precolumn (Phenomenex). The column oven temperature was + 28°C. The mobile phase consisted
448 of two eluents: A was 0.1 % formic acid in water and B was 0.1 % formic acid in methanol. The
449 HPLC gradient began and was held for 1 min at 10 % of B and was then ramped to reach 95 % at 7
450 min. Then B was decreased back to 10 % in 0.5 min and held there for 3.5 min. The run time was
451 11 min with a flow rate of 0.3 ml/min. Sample injection volume was 20 µl. The retention time of
452 dexmedetomidine and medetomidine-d₃ was approximately 5.5 min.

453 Mass spectrometric detection was carried out using positive Turbo Ion Spray (TIS) ionisation and
454 multiple reaction monitoring (MRM) mode. The ion source temperature was +500°C. The nebulizer
455 gas (Gas 1) and turbo gas (Gas 2) settings were 50. Curtain gas (nitrogen) was set to 16. The TIS
456 voltage setting was 5000 V. The selected reactions were as follows: for dexmedetomidine, the
457 precursor ion – fragment ion pair was m/z 201.2 - m/z 95.05, and for the deuterated internal
458 standard it was m/z 204.2 – m/z 98.05. The dwell time was 300 ms for both ion transitions. The

459 declustering potential was 55 V for both molecules. Entrance potential was 10 V. Collision energy
460 was 22 V. Collision cell exit potentials were 7 V and 6 V.

461 The calculations for the quantification were based on peak area ratios of the analyse and the internal
462 standard. The chromatograms were analysed and processed using AB Sciex software (Analyst®
463 version 1.6.3). The standard curves were generated using linear regression with $1/x^2$ weighting.

464

465 **Methods – Descriptive statistics**

Subject	Age	Sex	Height (cm)	Weight (kg)	BMI	Handedness	Responsive in deep sedation
1	21	Male	184	95	28.06	Right	False
2	22	Female	163	64	24.09	Right	True
3	26	Male	185	66	19.28	Right	False
4	24	Male	179	66	20.60	Right	False
5	25	Female	164	62	23.05	Right	False
6	23	Female	159	58	22.94	Right	False
7	23	Male	182	81	24.45	Right	False
8	28	Female	170	68	23.53	Right	True
9	24	Male	180	98	30.25	Right	True

10	27	Male	179	77	24.03	Right	False
11	24	Male	178	63	19.88	Right	False
12	24	Female	172	63	21.30	Right	True
13	22	Female	169	55	19.26	Right	False
14	19	Male	183	63	18.81	Right	False
15	24	Female	177	90	28.73	Left	True
16	26	Male	169	55	19.26	Left	False
17	19	Female	162	53	20.20	Right	False
18	24	Male	180	79	24.38	Left	True
19	27	Male	177	85	27.13	Left	True
20	25	Female	161	59	22.76	Right	False

Table A1: Demographics of participants, with age, weight, handedness and whether they were still responsive to verbal command with high doses of DEX.

Measurements	Region	Descriptive statistics			
		Baseline	Light sedation	Deep sedation	Recovery
Amplitude	Frontal	6.27 ± 3.29	12.46 ± 6.37	9.37 ± 3.36	10.22 ± 4.68

	Parietal	4.64 ± 4.12	6.10 ± 4.14	4.61 ± 3.84	5.18 ± 3.36
Slope	Frontal	0.91 ± 0.39	1.49 ± 0.69	1.09 ± 0.32	1.18 ± 0.42
	Parietal	0.58 ± 0.43	0.62 ± 0.42	0.47 ± 0.38	0.53 ± 0.35
Negative Latency	Frontal	9.10 ± 2.17	9.15 ± 1.69	9.05 ± 1.81	8.85 ± 1.90
	Parietal	11.10 ± 2.91	10.45 ± 2.21	11.45 ± 2.85	10.90 ± 2.24
Positive Latency	Frontal	21.35 ± 5.09	25.30 ± 4.33	25.05 ± 3.78	25.25 ± 4.58
	Parietal	23.85 ± 3.51	25.55 ± 4.26	26.55 ± 4.20	26.05 ± 3.55

469 **Table A2:** Mean and standard deviation (mean $\pm$ SD) of cortical excitability measurement for each
470 condition (baseline, light sedation, deep sedation, recovery), divided for region (frontal and
471 parietal).

472

Subject	Region	Electrode Distance (mm)	Induced EF (V/m)
1	Frontal	27.73	136.29
	Parietal	54.64	118.08
2	Frontal	31.40	113.52
	Parietal	42.94	147.47
3	Frontal	16.40	135.08
	Parietal	54.97	143.18
4	Frontal	35.23	105.54
	Parietal	47.42	134.18
5	Frontal	25.48	118.69
	Parietal	50.57	146.72
6	Frontal	31.11	119.22
	Parietal	31.06	132.39
7	Frontal	38.39	121.29
	Parietal	37.66	134.15

8	Frontal	44.10	118.32
	Parietal	38.54	104.93
9	Frontal	33.90	130.57
	Parietal	54.97	139.21
10	Frontal	36.69	110.97
	Parietal	65.40	98.95
11	Frontal	20.06	144.04
	Parietal	57.84	164.70
12	Frontal	23.32	125.36
	Parietal	52.70	145.11
13	Frontal	28.04	133.41
	Parietal	63.73	139.82
14	Frontal	58.86	125.15
	Parietal	51.62	130.96
15	Frontal	54.18	117.35
	Parietal	45.06	136.24
16	Frontal	16.06	130.50
	Parietal	58.15	119.71
17	Frontal	23.77	106.38
	Parietal	26.41	139.41
18	Frontal	27.68	125.81
	Parietal	27.30	138.20
19	Frontal	26.12	128.86
	Parietal	31.97	131.52
20	Frontal	25.06	120.28
	Parietal	55.15	144.03

473 **Table A3:** Distance of the electrode (mm) from the stimulation hotspot and induced electrical field
474 (V/m)

Results – Additional results of GLMM

Dependent Variables	Independent variable	
	Electric field (V/m)	Electrode Distance (mm)
Amplitude	$Z = 2.598$ $P = 0.009$	$Z = 1.357$ $P = 0.175$
Slope	$Z = 4.048$ $P < 0.001$	$Z = 1.988$ $P = 0.047$
Latency of negative peak*	$Z = /$ $P = /$	$Z = 1.388$ $P = 0.165$
Latency of positive peak	$Z = 0.602$ $P = 0.547$	$Z = 0.864$ $P = 0.387$

Table A4: Results of induced electric field caused by the TMS, and the distance of the electrode from the hotspot, for the four measures of cortical excitability. In **bold**, significant results, and in *italics* tendencies. Note that the induced electric field is not significant for amplitude ($P = 0.009$) as it is the primary endpoint and we have corrected for multiple comparison ($P_{\text{critical}} = 0.006$). SPSS reported that induced electric field was redundant for the negative peak and gave no results for it.

Results – GLMM without subjects with strong effect

To control the robustness of our results, we rerun the analysis excluding the subjects who showed the strongest results. As visible in **Figure 4**, two subjects presented relatively high amplitude (normalized amplitude > 3 standard deviations). The results without these two participants are virtually identical to the presented in the main text, showing a strong effect of condition over amplitude and slope, in particular in the frontal cortex. In **Figure A1**, we show the individual and average results by condition and cortical excitability parameters for all participants, while **Table A5** displays the significance of the results.




Figure A1: Averaged (black line) and individual results (grey line) of cortical excitability measurements (amplitude (A), slope (B), latency of negative peak (C) and latency of positive peak (D)) for the four conditions (baseline, light sedation, deep sedation, recovery). As **Figure 4**, divided in region (frontal vs. parietal), and with the standard error of the mean (SEM). The biggest change in the amplitude and slope appears in the frontal cortex during light sedation in comparison to the other three conditions. Legend: * = $p < 0.05$, ** = $p < 0.01$; *** = $p < 0.001$

Dependent Variables	Independent variables				
	Condition	Region (Frontal vs Parietal)	Condition* Region	DEX concentration	Responsiveness in deep sedation
Amplitude	$F_{(3, 133)} = 5.319$ $P < 0.001$	$F_{(1, 133)} = 9.352$ $P = 0.003$	$F_{(3, 133)} = 3.513$ $P = 0.017$	$F_{(1, 133)} = 3.709$ $P = 0.056$	$F_{(1, 133)} = 1.817$ $P = 0.180$
Slope	$F_{(3, 133)} = 6.552$ $P < 0.001$	$F_{(1, 133)} = 18.948$ $P < 0.001$	$F_{(3, 133)} = 3.716$ $P = 0.013$	$F_{(1, 133)} = 4.460$ $P = 0.037$	$F_{(1, 133)} = 0.052$ $P = 0.819$

Latency of negative peak	$F_{(3, 133)} = 0.171$ $P = 0.916$	$F_{(1, 133)} = \mathbf{10.555}$ $P = \mathbf{0.001}$	$F_{(3, 133)} = 0.329$ $P = 0.804$	$F_{(1, 133)} = 0.952$ $P = 0.331$	$F_{(1, 133)} = 0.056$ $P = 0.813$
Latency of positive peak	$F_{(3, 133)} = \mathbf{2.725}$ $P = \mathbf{0.047}$	$F_{(1, 133)} = \mathbf{9.887}$ $P = \mathbf{0.002}$	$F_{(3, 133)} = 1.431$ $P = 0.237$	$F_{(1, 133)} = 1.329$ $P = 0.251$	$F_{(1, 133)} = 0.651$ $P = 0.421$

Table A5. Results of the Generalized Linear Mixed Model (GLMM) on the modulation of cortical excitability, without the subjects who had the strongest effect. Significant factors are in **bold**. For contrast and estimate of the contrasts of amplitude and slope in the frontal region, see **Table A6**.

Pairwise comparisons in the frontal region					
Measure	Contrast	Estimate	Adjusted P	95% Confidence interval	
				Inferior	Superior
Amplitude	Baseline – Light	-4.891	<0.0001	-7.338	-2.444
	Baseline – Deep	-3.469	0.003	-6.043	-0.896
	Baseline – Recovery	-3.938	<0.001	-6.479	-1.398
	Light – Deep	1.422	0.144	-.306	3.149
	Light – Recovery	0.953	0.360	-.649	2.555
	Deep - Recovery	-0.469	0.360	-1.346	0.409
Slope	Baseline – Light	-0.457	<0.0001	-.726	-0.188
	Baseline – Deep	-0.269	0.042	-.531	-0.007
	Baseline – Recovery	-0.308	0.013	-.571	-0.045
	Light – Deep	0.188	0.042	0.004	0.372
	Light – Recovery	0.149	0.070	-0.009	0.308
	Deep - Recovery	-0.039	0.257	-0.106	0.029

Table A6: Post-hoc comparison for the amplitude and slope in the frontal cortex. Significant comparisons are represented in **bold**. Since amplitude is our main endpoint, its P_{critical} is set to 0.006, while for slope P_{critical} is 0.05.

Once these two participants were removed from the analyses, the general interpretation does not change: the effect of region is still present, with amplitude higher in frontal regions than in parietal

regions. Critically, pairwise differences are exactly the same (as before, no significance of parietal cortex; compare **Table 3** and **Table A6**), so that it is just a region-specific effect, with an unexpected higher cortical excitability in light sedation. However, there are minor differences to what it is reported in the main text concerning the interaction between region and condition for the amplitude, the effect of DEX concentration for the slope, and the effect of the region over the positive latency. The two subjects who showed the strongest effect had a significant effect over the frontal cortex. If we observe instead the effect of DEX blood concentration over the slope, we can appreciate an effect that was not present before. However, given that the DEX concentration changes according to the condition, it is not surprising. Finally, we see here an effect of region to the positive latency. As said in the discussion, every region creates different evoked potential when stimulated, that thus creates a specific TEP for that region. So, even if beyond the scope of our paper, it is reasonable that the positive latency changes, as the negative one did.

Dependent Variables	Independent variable	
	Electric field (V/m)	Electrode Distance (mm)
Amplitude	Z = 1.595 P = 0.111	Z = 2.211 P = 0.027
Slope	Z = 1.305 P = 0.192	Z = 1.732 P = 0.083
Latency of negative peak*	Z = / P = /	Z = 1.122 P = 0.262
Latency of positive peak	Z = 0.721 P = 0.471	Z = 1.422 P = 0.155

Table A7: Results of induced electric field caused by the TMS, and the distance of the electrode from the hotspot, for the four measures of cortical excitability. In **bold**, significant results, and in *italics* tendencies. Note that the induced electric field is not significant for amplitude (P = 0.009) as

527 it is the primary endpoint and we have corrected for multiple comparison ($P_{\text{critical}} = 0.006$). SPSS
528 reported that induced electric field was redundant for the negative peak and gave no results for it.

References

1. Bonhomme V, Staquet C, Montupil J, et al. General Anesthesia: A Probe to Explore Consciousness. *Front Syst Neurosci* [Internet] Frontiers Media SA; 2019 [cited 2019 Oct 4]; **13**: 36 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/31474839>
2. Sarasso S, Boly M, Napolitani M, et al. Consciousness and complexity during unresponsiveness induced by propofol, xenon, and ketamine. *Curr Biol* [Internet] Elsevier; 2015; **25**: 3099–105 Available from: <http://dx.doi.org/10.1016/j.cub.2015.10.014>
3. Bonhomme V, Vanhaudenhuyse A, Demertzi A, et al. Resting-state Network-specific Breakdown of Functional Connectivity during Ketamine Alteration of Consciousness in Volunteers. *Anesthesiology* Lippincott Williams and Wilkins; 2016; **125**: 873–88
4. Darracq M, Funk CM, Polyakov D, et al. Evoked Alpha Power is Reduced in Disconnected Consciousness During Sleep and Anesthesia. *Sci Rep* [Internet] Springer US; 2018; **8**: 16664 Available from: <http://www.nature.com/articles/s41598-018-34957-9>
5. Evered L, Silbert B, Knopman DS, et al. Recommendations for the nomenclature of cognitive change associated with anaesthesia and surgery—2018 [Internet]. *Br. J. Anaesth.* Elsevier Ltd; 2018 [cited 2020 Aug 29]. p. 1005–12 Available from: <https://doi.org/10.1016/j.bja.2017.12.029>.
6. Zhang J, Yu Y, Miao S, et al. Effects of peri-operative intravenous administration of dexmedetomidine on emergence agitation after general anesthesia in adults: a meta-analysis of randomized controlled trials. *Drug Des Devel Ther* 2019; **13**: 2853–64
7. Duan X, Coburn M, Rossaint R, Sanders RD, Waesberghe J V, Kowark A. Efficacy of perioperative dexmedetomidine on postoperative delirium: systematic review and meta-analysis with trial sequential analysis of randomised controlled trials. *Br J Anaesth* England; 2018; **121**: 384–97
8. Djaiani G, Silverton N, Fedorko L, et al. Dexmedetomidine versus Propofol Sedation

- 554 Reduces Delirium after Cardiac Surgery: A Randomized Controlled Trial. *Anesthesiology*
- 555 Lippincott Williams and Wilkins; 2016; **124**: 362–8
- 556 9. Purdon PL, Sampson A, Pavone KJ, Brown EN. Clinical electroencephalography for
- 557 anesthesiologists. *Anesthesiology*. Lippincott Williams and Wilkins; 2015. p. 937–60
- 558 10. Yu X, Franks NP, Wisden W. Sleep and Sedative States Induced by Targeting the Histamine
- 559 and Noradrenergic Systems. *Front Neural Circuits* [Internet] 2018 [cited 2019 Feb 4]; **12**
- 560 Available from: www.frontiersin.org
- 561 11. Guldenmund P, Vanhaudenhuyse A, Sanders RD, et al. Brain functional connectivity
- 562 differentiates dexmedetomidine from propofol and natural sleep. *Br J Anaesth* [Internet] The
- 563 Author(s); 2017 [cited 2019 Nov 23]; **119**: 674–84 Available from:
- 564 <http://dx.doi.org/10.1093/bja/aex257>
- 565 12. Akeju O, Loggia ML, Catana C, et al. Disruption of thalamic functional connectivity is a
- 566 neural correlate of dexmedetomidine-induced unconsciousness. *Elife* eLife Sciences
- 567 Publications Ltd; 2014; **3**: 1–23
- 568 13. Hashmi JA, Loggia ML, Khan S, et al. Dexmedetomidine Disrupts the Local and Global
- 569 Efficiencies of Large-scale Brain Networks. *Anesthesiology* [Internet] Lippincott Williams
- 570 and Wilkins; 2017 [cited 2020 Aug 29]; **126**: 419–30 Available from:
- 571 <https://pubmed.ncbi.nlm.nih.gov/28092321/>
- 572 14. Kallionpää RE, Scheinin A, Kallionpää RA, et al. Spoken words are processed during
- 573 dexmedetomidine-induced unresponsiveness. *Br J Anaesth* Elsevier Ltd; 2018; **121**: 270–80
- 574 15. Akeju O, Kim SE, Vazquez R, et al. Spatiotemporal dynamics of dexmedetomidine-induced
- 575 electroencephalogram oscillations. *PLoS One* Public Library of Science; 2016; **11**
- 576 16. Scheinin A, Kallionpää RE, Li D, et al. Differentiating drug-related and state-related effects
- 577 of dexmedetomidine and propofol on the electroencephalogram. *Anesthesiology* Lippincott
- 578 Williams and Wilkins; 2018; **129**: 22–36
- 579 17. Sleight JW, Vacas S, Flexman AM, Talke PO. Electroencephalographic arousal patterns

- 580 under dexmedetomidine sedation. *Anesth Analg* Lippincott Williams and Wilkins; 2018; **127**:
- 581 951–9
- 582 18. Massimini M, Ferrarelli F, Murphy MJ, et al. Cortical reactivity and effective connectivity
- 583 during REM sleep in humans. *Cogn Neurosci* [Internet] NIH Public Access; 2010 [cited
- 584 2019 Sep 18]; **1**: 176–83 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20823938>
- 585 19. Huber R, Mäki H, Rosanova M, et al. Human cortical excitability increases with time awake.
- 586 *Cereb Cortex* [Internet] 2013 [cited 2019 May 31]; **23**: 332–8 Available from:
- 587 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539451/pdf/bhs014.pdf>
- 588 20. Ly JQM, Gaggioni G, Chellappa SL, et al. Circadian regulation of human cortical
- 589 excitability. *Nat Commun* [Internet] 2016; **7**: 11828 Available from:
- 590 <http://www.nature.com/doi/10.1038/ncomms11828>
- 591 21. Massimini M, Ferrarelli F, Huber R, Esser SK. Breakdown of Cortical Effective
- 592 Connectivity During Sleep. *Science (80-)* 2005; **309**: 2228–33
- 593 22. Cardone P, Van Egroo M, Chylinski D, Narbutas J, Gaggioni G, Vandewalle G. Increased
- 594 cortical excitability but stable effective connectivity index during attentional lapses. *Sleep*
- 595 [Internet] 2020 [cited 2020 Dec 29]; Available from:
- 596 <https://academic.oup.com/sleep/advance-article/doi/10.1093/sleep/zsaa284/6046202>
- 597 23. Dyck JB, Maze M, Haack C, Azarnoff DL, Vuorilehto L, Shafer SL. Computer-controlled
- 598 infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers.
- 599 *Anesthesiology* 1993; **78**: 821–8
- 600 24. Malviya S, Voepel-Lewis T, Tait AR, Merkel S, Tremper K, Naughton N. Depth of sedation
- 601 in children undergoing computed tomography: validity and reliability of the University of
- 602 Michigan Sedation Scale (UMSS). *Br J Anaesth* [Internet] 2002 [cited 2019 Nov 23]; **88**:
- 603 241–5 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0007091217365352>
- 604 25. Ramsay MAE, Savege TM, Simpson BRJ, Goodwin R. Controlled Sedation with
- 605 Alphaxalone-Alphadolone. *Br Med J* 1974; **2**: 656–9

- 606 26. Rosanova M, Fecchio M, Casarotto S, et al. Sleep-like cortical OFF-periods disrupt causality
607 and complexity in the brain of unresponsive wakefulness syndrome patients. *Nat Commun*
608 [Internet] Nature Publishing Group; 2018 [cited 2019 Sep 18]; **9**: 4427 Available from:
609 <http://www.nature.com/articles/s41467-018-06871-1>
- 610 27. Sachdev RNS, Ebner FF, Wilson CJ. Effect of subthreshold up and down states on the
611 whisker-evoked response in somatosensory cortex. *J Neurophysiol* [Internet] J Neurophysiol;
612 2004 [cited 2021 Apr 25]; **92**: 3511–21 Available from:
613 <https://pubmed.ncbi.nlm.nih.gov/15254074/>
- 614 28. Wörgötter F, Suder K, Zhao Y, Kerscher N, Eysel UT, Funke K. State-dependent receptive-
615 field restructuring in the visual cortex. *Nature* [Internet] Nature Publishing Group; 1998
616 [cited 2021 Apr 25]; **396**: 165–8 Available from: www.nature.com
- 617 29. Bazhenov M, Timofeev I, Steriade M, Sejnowski TJ. Model of thalamocortical slow-wave
618 sleep oscillations and transitions to activated states. *J Neurosci* [Internet] Society for
619 Neuroscience; 2002 [cited 2021 Apr 25]; **22**: 8691–704 Available from:
620 <https://pubmed.ncbi.nlm.nih.gov/12351744/>
- 621 30. Hill S, Tononi G. Modeling sleep and wakefulness in the thalamocortical system. *J*
622 *Neurophysiol* [Internet] J Neurophysiol; 2005 [cited 2021 Apr 25]; **93**: 1671–98 Available
623 from: <https://pubmed.ncbi.nlm.nih.gov/15537811/>
- 624 31. Noreika V, Kamke M, Canales-Johnson A, Chennu S, Bekinschtein T, Mattingley J.
625 Alertness fluctuations during task performance modulate cortical evoked responses to
626 transcranial magnetic stimulation. *Neuroimage* [Internet] 2020 [cited 2020 Sep 2]; 155754
627 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1053811920307916>
- 628 32. Boly M, Massimini M, Tsuchiya N, Postle BR, Koch C, Tononi G. Are the Neural Correlates
629 of Consciousness in the Front or in the Back of the Cerebral Cortex? Clinical and
630 Neuroimaging Evidence. *J Neurosci* [Internet] Society for Neuroscience; 2017 [cited 2019
631 Sep 6]; **37**: 9603–13 Available from: <https://www.jneurosci.org/content/37/40/9603>

- 632 33. Ziemann U. TMS and drugs. Clin. Neurophysiol. Elsevier; 2004. p. 1717–29
- 633 34. Tran DMD, McNair NA, Harris JA, Livesey EJ. Expected TMS excites the motor system
634 less effectively than unexpected stimulation. *Neuroimage* Academic Press Inc.; 2021; **226**:
635 117541
- 636 35. Darmani G, Bergmann TO, Zipser C, Baur D, Müller-Dahlhaus F, Ziemann U. Effects of
637 antiepileptic drugs on cortical excitability in humans: A TMS-EMG and TMS-EEG study.
638 *Hum Brain Mapp* 2019; **40**: 1276–89
- 639 36. Fecchio M, Pigorini A, Comanducci A, et al. The spectral features of EEG responses to
640 transcranial magnetic stimulation of the primary motor cortex depend on the amplitude of the
641 motor evoked potentials. *PLoS One* 2017; **12**: 1–15
- 642 37. Rosanova M, Casali A, Bellina V, Resta F, Mariotti M, Massimini M. Natural frequencies of
643 human corticothalamic circuits. *J Neurosci* [Internet] 2009 [cited 2020 May 12]; **29**: 7679–85
644 Available from: www.jneurosci.org
- 645 38. Herring JD, Thut G, Jensen O, Bergmann TO. Attention modulates TMS-locked alpha
646 oscillations in the visual cortex. *J Neurosci* 2015; **35**: 14435–47
- 647 39. Bergmann TO, Molle M, Schmidt MA, et al. EEG-Guided Transcranial Magnetic
648 Stimulation Reveals Rapid Shifts in Motor Cortical Excitability during the Human Sleep
649 Slow Oscillation. *J Neurosci* 2012; **32**: 243–53
- 650 40. Shin H, Law R, Tsutsui S, Moore CI, Jones SR. The rate of transient beta frequency events
651 predicts behavior across tasks and species. *Elife* [Internet] 2017 [cited 2019 Jun 17]; **6**
652 Available from: <https://doi.org/10.7554/eLife.29086.001>
- 653 41. Ballesteros JJ, Briscoe JB, Ishizawa Y. Neural signatures of α 2-adrenergic agonist-induced
654 unconsciousness and awakening by antagonist. *Elife* [Internet] 2020; **9**: 1–18 Available from:
655 <https://elifesciences.org/articles/57670>
- 656 42. Sanders RD, Tononi G, Laureys S, Sleigh JW. Unresponsiveness $\neq$ unconsciousness.
657 *Anesthesiology*. 2012. p. 946–59

- 658 43. Xi C, Sun S, Pan C, Ji F, Cui X, Li T. Different effects of propofol and dexmedetomidine
659 sedation on electroencephalogram patterns: Wakefulness, moderate sedation, deep sedation
660 and recovery. *PLoS One* Public Library of Science; 2018; **13**
661